327 related articles for article (PubMed ID: 32986864)
1. Osteopontin Takes Center Stage in Chronic Liver Disease.
Song Z; Chen W; Athavale D; Ge X; Desert R; Das S; Han H; Nieto N
Hepatology; 2021 Apr; 73(4):1594-1608. PubMed ID: 32986864
[TBL] [Abstract][Full Text] [Related]
2. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin - A potential biomarker of advanced liver disease.
Bruha R; Vitek L; Smid V
Ann Hepatol; 2020; 19(4):344-352. PubMed ID: 32005637
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases.
Wang G; Chen S; Zhao C; Li X; Zhao W; Yang J; Chang C; Xu C
J Genet; 2016 Sep; 95(3):741-50. PubMed ID: 27659347
[TBL] [Abstract][Full Text] [Related]
5. Role of Osteopontin in Liver Diseases.
Wen Y; Jeong S; Xia Q; Kong X
Int J Biol Sci; 2016; 12(9):1121-8. PubMed ID: 27570486
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation.
Seth D; Duly A; Kuo PC; McCaughan GW; Haber PS
World J Gastroenterol; 2014 Sep; 20(36):13088-104. PubMed ID: 25278703
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines.
Chae S; Jun HO; Lee EG; Yang SJ; Lee DC; Jung JK; Park KC; Yeom YI; Kim KW
Int J Oncol; 2009 Dec; 35(6):1409-16. PubMed ID: 19885563
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin delays resolution of liver fibrosis.
Leung TM; Wang X; Kitamura N; Fiel MI; Nieto N
Lab Invest; 2013 Oct; 93(10):1082-9. PubMed ID: 23999249
[TBL] [Abstract][Full Text] [Related]
9. Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.
Lee JH; Banerjee A; Ueno Y; Ramaiah SK
Toxicol Sci; 2008 Nov; 106(1):290-9. PubMed ID: 18703563
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer.
Macek-Jilkova Z; Malov SI; Kurma K; Charrat C; Decaens T; Peretolchina NP; Marche PN; Malov IV; Yushchuk ND
Bull Exp Biol Med; 2021 Jan; 170(3):340-344. PubMed ID: 33452981
[TBL] [Abstract][Full Text] [Related]
11. Higher Matrix Stiffness Upregulates Osteopontin Expression in Hepatocellular Carcinoma Cells Mediated by Integrin β1/GSK3β/β-Catenin Signaling Pathway.
You Y; Zheng Q; Dong Y; Wang Y; Zhang L; Xue T; Xie X; Hu C; Wang Z; Chen R; Wang Y; Cui J; Ren Z
PLoS One; 2015; 10(8):e0134243. PubMed ID: 26280346
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes.
Iqbal J; McRae S; Banaudha K; Mai T; Waris G
J Biol Chem; 2013 Dec; 288(52):36994-7009. PubMed ID: 24240095
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer.
Ramaiah SK; Rittling S
Toxicol Sci; 2008 May; 103(1):4-13. PubMed ID: 17890765
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up.
Cabiati M; Gaggini M; Cesare MM; Caselli C; De Simone P; Filipponi F; Basta G; Gastaldelli A; Del Ry S
Cytokine; 2017 Nov; 99():59-65. PubMed ID: 28711012
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice.
Lancha A; Rodríguez A; Catalán V; Becerril S; Sáinz N; Ramírez B; Burrell MA; Salvador J; Frühbeck G; Gómez-Ambrosi J
PLoS One; 2014; 9(5):e98398. PubMed ID: 24871103
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease.
Tang M; Jiang Y; Jia H; Patpur BK; Yang B; Li J; Yang C
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):159-168. PubMed ID: 31852298
[TBL] [Abstract][Full Text] [Related]
19. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
20. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
Nardo AD; Grün NG; Zeyda M; Dumanic M; Oberhuber G; Rivelles E; Helbich TH; Markgraf DF; Roden M; Claudel T; Trauner M; Stulnig TM
Liver Int; 2020 Jul; 40(7):1620-1633. PubMed ID: 32281248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
